Day: January 4, 2022

Vancouver, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon”) (TSX-V: CYL) (OTC:CYLYF) (FSE: CCY) is pleased to announce receipt of the renewal of its Environmental Protection Licence from the Central Environmental Authority of Sri Lanka for ongoing operations at the K1 Mine. The Licence is valid for three years after having past an inspection that the operation conforms to stipulated standards. Ceylon CEO, Don Baxter stated, “We are very pleased with our technical staff on site, having maintained compliance with the applicable environmental standards and we look forward to applying these standards to our production growth vein graphite prospects in Sri Lanka.” Environmental, Social, and Governance (ESG) factors have become an increasingly important part of the investing and off-take process. Ceylon...

DigitalAMN Acquired Rights to .hiphop in Partnership With Domain Name Industry Experts, to Help Promote Equitability and Opportunity for the Hip Hop Culture NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Digital Asset Monetary Network, Inc. (“DigitalAMN”, “DAMN”, or the “Company”) (OTCMKTS: DATI), a Public Accelerator-Incubator (“PAI”), announced today, that in partnership with highly experienced Domain Name industry executive-entrepreneurs, the Company has acquired the rights to the Top-Level-Domain (“TLD”), .hiphop, through Dot Hip Hop, LLC (“Dot Hip Hop”)—whose partnership is listed in the Company’s 3rd QT Financial Disclosures [2021]. The Company initially made this announcement without identifying the name of the TLD (or “gTLD” (generic Top-Level-Domain)) as .hiphop. This was done to preserve the integrity of the assignment process...

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Warner Music Group Corp. (“Warner Music Group”) (Nasdaq: WMG) today announced the pricing of an underwritten secondary offering (the “offering”) of an aggregate of 8,562,500 shares of Warner Music Group’s Class A common stock (“common stock”) by affiliates of Access Industries, LLC, at a price to the public of $41.00 per share. The offering is expected to close on January 6, 2022. Warner Music Group is not selling any shares of common stock in the offering and will not receive any of the proceeds. Morgan Stanley is acting as the underwriter for the offering. A shelf registration statement (including a prospectus) relating to the common stock has been filed with the SEC and has become effective. The offering is being made only by means of a prospectus supplement and an accompanying prospectus....

Onsite testing to enable significant production expansion ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has taken delivery of key lab equipment to Prodigy Textiles, the Company’s Vietnam based subsidiary, to support onsite testing and screening of spider silk transgenic technologies. Over the next few weeks, the Company’s US-based research team will work closely with the Prodigy team to complete equipment installation and conduct training. Once online, this equipment will allow for the complete transfer of all genetic screening and selection testing, for production operations, to Prodigy’s onsite lab. The significance of this advancement in the...

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that The Lancet Diabetes & Endocrinology has published the full results of the global Phase 3 MPOWERED clinical trial that compared Mycapssa® (oral octreotide capsules) to long-acting injectable Somatostatin Receptor Ligands (iSRLs) for maintenance of biochemical response in patients with acromegaly. The MPOWERED trial was designed to support the marketing authorization application for Mycapssa® to the EMA which is currently under evaluation....

Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindnessLEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last visit (Month 12) in the Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation, also known as c.2991+1655A>G. “The last patient having completed their 12 Month visit is an important milestone toward the top-line results from the Phase 2/3 Illuminate trial of our...

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist supportLondon, UK – 4 January 2022         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, shared results today of a phase I study showing the feasibility of administering COMP360 psilocybin to up to six healthy participants simultaneously, with 1:1 support. The study, peer-reviewed and published in The Journal of Psychopharmacology as “The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase I, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation1“, was conducted...

Clinical evidence supporting the company’s platform for nerve repair will be featured in several presentations during the scientific sessions ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM). The meetings will be held January 11-18, 2022 in Carlsbad, CA. Axogen will host an educational symposium on Thursday, January 13th at 1:00 p.m. featuring modern approaches to nerve repair and reconstruction. Data in Decision Making: The sensible, modern...

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) — Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022. The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00 am ET and can be accessed by visiting the “Investors” page under the “Events & Presentation” section of the Prelude website, where a replay of the presentation will be available for a limited time. About Prelude Therapeutics Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Prelude’s initial clinical...